A small semaglutide implant from American biotech company Vivani Medical. Capture from Vivany Medical website: Pharmaceutical companies' 'second round' is in full swing regarding the future obesity treatment market, which is expected to be worth $100 billion (approximately 150 trillion won). If the first round declared the popularization of the ‘era of losing weight with medicine’, this time the axis of competition between companies is diversifying through patient convenience, expansion of indications, and minimization of side effects...